The contingent value right (CVR) offered by BMS as a sweetener for the $74 billion takeover of Celgene in 2019 is defunct, as one of the three drugs – CAR-T therapy liso-cel for lymphoma ...
The headline news is that Celgene chief executive Mark Alles is heading for the door, and there’s also no room for BMS’ recently-appointed chief scientific officer Thomas Lynch in the combined ...
The suit was filed in June 2021. Bristol Myers acquired Celgene in 2019 for $74B. Under the deal, Celgene shareholders ...
Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new ... in the first 9 months of 2024, but BMS expects an "additional step down” to $2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback